Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

669 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Exploiting tumour hypoxia in cancer treatment.
Brown JM, Wilson WR. Brown JM, et al. Nat Rev Cancer. 2004 Jun;4(6):437-47. doi: 10.1038/nrc1367. Nat Rev Cancer. 2004. PMID: 15170446 Review. No abstract available.
Identification of P450 Oxidoreductase as a Major Determinant of Sensitivity to Hypoxia-Activated Prodrugs.
Hunter FW, Young RJ, Shalev Z, Vellanki RN, Wang J, Gu Y, Joshi N, Sreebhavan S, Weinreb I, Goldstein DP, Moffat J, Ketela T, Brown KR, Koritzinsky M, Solomon B, Rischin D, Wilson WR, Wouters BG. Hunter FW, et al. Cancer Res. 2015 Oct 1;75(19):4211-23. doi: 10.1158/0008-5472.CAN-15-1107. Epub 2015 Aug 21. Cancer Res. 2015. PMID: 26297733
Hypoxia-activated prodrugs: paths forward in the era of personalised medicine.
Hunter FW, Wouters BG, Wilson WR. Hunter FW, et al. Br J Cancer. 2016 May 10;114(10):1071-7. doi: 10.1038/bjc.2016.79. Epub 2016 Apr 12. Br J Cancer. 2016. PMID: 27070712 Free PMC article. Review.
Homologous recombination is the principal pathway for the repair of DNA damage induced by tirapazamine in mammalian cells.
Evans JW, Chernikova SB, Kachnic LA, Banath JP, Sordet O, Delahoussaye YM, Treszezamsky A, Chon BH, Feng Z, Gu Y, Wilson WR, Pommier Y, Olive PL, Powell SN, Brown JM. Evans JW, et al. Cancer Res. 2008 Jan 1;68(1):257-65. doi: 10.1158/0008-5472.CAN-06-4497. Cancer Res. 2008. PMID: 18172318
Targeting hypoxia in cancer therapy.
Wilson WR, Hay MP. Wilson WR, et al. Nat Rev Cancer. 2011 Jun;11(6):393-410. doi: 10.1038/nrc3064. Nat Rev Cancer. 2011. PMID: 21606941 Review.
A phase I trial of PR-104, a pre-prodrug of the bioreductive prodrug PR-104A, given weekly to solid tumour patients.
McKeage MJ, Gu Y, Wilson WR, Hill A, Amies K, Melink TJ, Jameson MB. McKeage MJ, et al. BMC Cancer. 2011 Oct 7;11:432. doi: 10.1186/1471-2407-11-432. BMC Cancer. 2011. PMID: 21982454 Free PMC article. Clinical Trial.
DNA cross-links in human tumor cells exposed to the prodrug PR-104A: relationships to hypoxia, bioreductive metabolism, and cytotoxicity.
Singleton RS, Guise CP, Ferry DM, Pullen SM, Dorie MJ, Brown JM, Patterson AV, Wilson WR. Singleton RS, et al. Cancer Res. 2009 May 1;69(9):3884-91. doi: 10.1158/0008-5472.CAN-08-4023. Epub 2009 Apr 14. Cancer Res. 2009. PMID: 19366798
Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia.
Denny WA, Wilson WR. Denny WA, et al. Expert Opin Investig Drugs. 2000 Dec;9(12):2889-901. doi: 10.1517/13543784.9.12.2889. Expert Opin Investig Drugs. 2000. PMID: 11093359 Review.
669 results
Jump to page
Feedback